240 related articles for article (PubMed ID: 34902803)
1. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.
Pelletier AN; Sekaly RP; Tomalka JA
Curr Opin Virol; 2022 Feb; 52():89-101. PubMed ID: 34902803
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
3. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
4. The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges.
Malik JA; Ahmed S; Mir A; Shinde M; Bender O; Alshammari F; Ansari M; Anwar S
J Infect Public Health; 2022 Feb; 15(2):228-240. PubMed ID: 35042059
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
[TBL] [Abstract][Full Text] [Related]
6. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
7. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries.
Hussain A; Rafeeq H; Asif HM; Shabbir S; Bilal M; Mulla SI; Franco M; Iqbal HMN
Int Immunopharmacol; 2021 Oct; 99():108050. PubMed ID: 34426120
[TBL] [Abstract][Full Text] [Related]
8. The COVID-19 pandemic: viral variants and vaccine efficacy.
Ciotti M; Ciccozzi M; Pieri M; Bernardini S
Crit Rev Clin Lab Sci; 2022 Jan; 59(1):66-75. PubMed ID: 34598660
[TBL] [Abstract][Full Text] [Related]
9. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
[TBL] [Abstract][Full Text] [Related]
10. Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint.
Chen X; Wang W; Chen X; Wu Q; Sun R; Ge S; Zheng N; Lu W; Yang J; Rodewald L; Yu H
BMC Med; 2022 Jan; 20(1):36. PubMed ID: 35086547
[TBL] [Abstract][Full Text] [Related]
11. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.
Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C
J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758
[TBL] [Abstract][Full Text] [Related]
12. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
13. Development of vaccines for SARS-CoV-2.
Ng WH; Liu X; Mahalingam S
F1000Res; 2020; 9():. PubMed ID: 32850116
[TBL] [Abstract][Full Text] [Related]
14. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
15. Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic.
Tsakiri M; Naziris N; Demetzos C
Int J Pharm; 2021 Dec; 610():121212. PubMed ID: 34687816
[TBL] [Abstract][Full Text] [Related]
16. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines.
Singh DD; Parveen A; Yadav DK
Front Cell Infect Microbiol; 2021; 11():777212. PubMed ID: 34970509
[TBL] [Abstract][Full Text] [Related]
18. Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and Streptococcus pneumoniae.
Deng Y; Li J; Sun C; Chi H; Luo D; Wang R; Qiu H; Zhang Y; Wu M; Zhang X; Huang X; Xie L; Qin C
Adv Mater; 2022 May; 34(21):e2200443. PubMed ID: 35332581
[TBL] [Abstract][Full Text] [Related]
19. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
